KRAS mutations predict sensitivity to pemetrexed-based chemotherapy

Author： Levy Benjamin Drilon Alexander Chachoua Abraham Seetharamu Nagashree Richardson Stacy Lucido David Legasto Alan Grossbard Michael Becker Daniel

Publisher： Future Medicine

ISSN： 1758-1966

Source： Lung Cancer Management, Vol.2, Iss.4, 2013-08, pp. : 275-280

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced nonsmall cell lung cancer patients treated with pemetrexedbased chemotherapy

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1165-1170

Spandidos Publications

Access to resources Recommend Favorite

TP53 oncomorphic mutations predict resistance to platinum and taxanebased standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma

International Journal of Oncology, Vol. 46, Iss. 2, 2015-01 ,pp. : 607-618

Spandidos Publications

Access to resources Recommend Favorite

The Importance of Balancing Toxicity and Efficacy in Chemotherapy: Focus on Pemetrexed

By Boyer Michael

American Journal of Cancer, Vol. 4, Iss. 2, 2005-01 ,pp. : 127-136

Adis International

Access to resources Recommend Favorite

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F Febbo Phillip G

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations

By Iwamoto Takayuki

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 155-164

Springer Publishing Company

Access to resources Recommend Favorite